Do you want to skip to content? Skip to content
Contact Us Convatec Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本
Convatec Convatec False /oidc-signin/en-us/

Most visited pages

Reports, results and presentations
Contact Us Convatec Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本

04 August 2022

Download press release

PDF Download

 

Convatec Group Plc
Interim Results for the six months ended 30 June 2022

Strong revenue growth, stable adjusted operating profit and continued strategic progress

  • Good financial performance in H1 2022 notwithstanding the challenging inflationary backdrop and continued investment in Innovation, Sales & Marketing
  • Continued execution of FISBE (Focus, Innovate, Simplify, Build, Execute) strategy in H1, notably:

    o Entry into Wound Biologics1 segment; exit from non-core hospital care and related industrial sales activities

    o Further progress with our new product pipeline; launch of GentleCath Air Male in France and InnovaMatrix in US; acquired a minority stake in BlueWind Medical

    o Simplification and efficiency initiatives supporting reduction in adjusted G&A to 9.7% of sales (H1 2021: 11.1%)

    o Positive pricing performance and new Convatec masterbrand launched

    o Progress embedding ‘Convatec Cares’, our new Environmental, Social & Governance (ESG) framework

  • On track to deliver full year guidance – further demonstration Convatec is pivoting to sustainable and profitable growth

Key financial highlights

table

 

  • Strong revenue growth: Reported +3.6% although significant FX headwind. +8.0% on a constant currency4 basis and +6.4% on an organic4 basis with positive performances across all divisions
  • Reported operating profit 35.7% lower primarily reflecting hospital care exit costs
  • Stable adjusted2 operating profit: +0.0% and +1.1% on a constant currency3 basis despite significant COGS inflation of c.7% and investments in Sales & Marketing and R&D operating
    expense of 15% on a constant currency basis
  • Adjusted2 operating profit margin was 19.6% (H1 2021: 20.3%) with price/mix, productivity improvement, G&A reduction and FX tailwind more than offset by inflation and the
    operating expense investments. Operating costs will be more evenly phased across the year in 2022 than in 2021.
  • Reported diluted EPS down 43.9% principally owing to the hospital care exit cost. Adjusted2 diluted EPS down 10.0% primarily owing to treatment of US deferred tax; excluding the recognition of deferred tax assets post the acquisitions, the adjusted EPS would have been down 2.7%
  • Net debt2 increased by $196 million largely owing to strategic M&A investments: leverage of 2.3x net debt2/adjusted EBITDA2 (FY 2021: 1.9x)
  • Interim dividend of 1.717 cents declared (H1 2021: 1.717)

2022 outlook confirmed

Convatec is on track to deliver organic4 revenue growth of 4.0-5.5% and constant currency
adjusted operating profit3 margin of at least 18%, as indicated in March 2022, notwithstanding
the current inflationary backdrop.

Karim Bitar, Chief Executive Officer, commented:

“This performance demonstrates that Convatec is continuing to pivot to sustainable and profitable growth. Our competitive position and financial performance are strengthening as we successfully execute our FISBE strategy. Convatec has achieved strong sales growth and,
despite the significant inflationary back drop, a robust profit performance. We are confirming our guidance for the full year.”

“We remain focused on executing our strategy and are confident in Convatec’s ability to grow in line or faster than its markets and to improve its operating margin to mid-20% over time.”

--------------------------------------------------------------

(1) Wound Biologics segment as defined by SmartTRAK. Includes skin substitutes, active collagen dressings and topical drug delivery.
(2) Certain financial measures in this document, including adjusted results above, are not prepared in accordance with International Financial Reporting
Standards ("IFRS"). All adjusted measures are reconciled to the most directly comparable measure prepared in accordance with IFRS in the Nonā€IFRS Financial Information below (pages 37 to 43).
(3) Constant currency growth is calculated by applying the applicable prior period average exchange rates to the Group's actual performance in the respective period.
(4) Organic growth presents period over period growth at constant currency, adjusted for: Triad Life Sciences (Mar’22), Cure Medical (Mar’21) and Patient Care Medical (Dec’21) acquisitions; Incontinence divestment (Dec’21) and, from 31st May, the discontinuation of Hospital care and related industrial sales and the reconfigured business in Russia.

Download the full text of this announcement

PDF Download

 

 

Analysts and Investors

ir@convatec.com

Kate Postans
Vice President of Investor Relations & Corporate Communications  

+44 (0)7826 447807

Media

 

Buchanan: Charles Ryland / Chris Lane   

+44 (0)207 466 5000

 

Press Release

See all

11/17/2022

Capital Markets Event

Read more

11/10/2022

Trading Update for the 10 months ended 31 October 2022

Read more

8/4/2022

Interim Results for the six months ended 30 June 2022

Read more

5/12/2022

Entry into the attractive wound biologics segment through the acquisition of Triad Life Sciences Inc

Read more

2/28/2022

Non-Executive Directors - Appointment and Resignation

Read more

3/8/2022

Annual Results for the twelve months ended 31 December 2021

Read more

3/14/2022

Convatec Group completes acquisition of Triad Life Sciences Inc as it enters attractive wound biologics segment

Read more

5/13/2022

Convatec invests in BlueWind Medical to fund development of innovative neuromodulation technology

Read more

5/12/2022

AGM trading update for the four months ended 30 April 2022

Read more

1/27/2022

Board committee changes

Read more

5/18/2022

Convatec makes 'forever caring' promise to patients and healthcare providers

Read more